Abstract:T he study by Guo et al examines the in vitro protective effect of culture supernatants from 2 probiotic bacteria, Bifidobacterium infantis and Lactobacillus acidophilus, on intestinal epithelial barrier function. Using an epithelial colorectal adenocarcinoma cell line (Caco-2) assay, the authors demonstrate that preincubation with sterile, cell-free culture supernatants (CFS) from either of these 2 bacterial strains prevented interleukin-1b-induced intestinal barrier permeability as measured by transepithelial electrical resistance and fluorescein isothiocyanate-labeled dextran flux. Protection was mediated by preventing both interleukin-1b-induced increases in tight junction protein claudin-1 expression and nuclear factor-kB activation. These observations add to a growing body of evidence that probiotic bacteria and, more specifically, their cell-associated and secreted products promote integrity of epithelial barrier function and maintenance of intestinal homeostasis (1–4). pH is a key determinant of bioactivity; L acidophilus and B infantis used in this study produce lactate that acidifies the conditioned culture medium and likely influences the bioactivity of associated microbial-derived products. In the described study, the authors adjust the cell-free supernatant to pH 7.4. Luminal pH in the healthy lower gastrointestinal tract is, however, site-specific and ranges from 5.5 to 7.5 (though patients with gastrointestinal disease frequently exhibit deviations from these mean values (5)). This raises the possibility that the bioactivity of the CFS in vitro may be distinct from in vivo conditions in the gastrointestinal tract and supports screening the bioactivity of these conditioned culture media across the range of pH conditions found in the lower gut. Questions also naturally arise as to whether this beneficial effect of probiotic strain-derived CFS is exclusive to these probiotic species, or if CFS from other bacteria, including those typically considered pathogenic, may also derive a similar effect under the epithelial culture conditions examined. Although it is critical to understand the efficacy of single species and the mechanisms by which they promote barrier function, the complex microbial communities found in the gastrointestinal tract (human microbiome), even in the earliest phases of life, may influence bioavailability of consumed or orally administered bioactives. Microbial members within the human gastrointestinal microbiome compete with each other and the host for resources. To date, the microbial-derived products that promote barrier function include short-chain fatty acids such as acetate produced by Bifidobacteria, which prevent epithelial barrier disruption through tumor necrosis factor-a induction (1). Such products, however, represent attractive carbon sources for a broad range of gastrointestinal organisms (6–8). Hence, whether oral supplementation with probiotic-derived products would lead to effective epithelial bioavailbility in the distal gastrointestinal tract in humans remains to be determined. Ideally, a single microbial-derived product within the conditioned media of these species promotes epithelial integrity. There are, however, multiple candidate mechanisms and likely as many microbial-derived and associated products that may promote barrier function. These may include pH modification via production of lactic acid or other short-chain fatty acids (7), lipid-derived induction of anti-inflammatory innate and adaptive immune responses (9), and/or triggering of toll-like receptor signaling pathways (4,10), which may act synergistically to promote epithelial integrity. Moreover, the gastrointestinal tract is overtly colonized from early life, so while promoting barrier function may reduce proinflammatory responses it is unlikely to correct associated gut microbial dysbioses. As such, the efficacy of such a therapeutic strategy may be enhanced by preconditioning the gastrointestinal tract with microbial-derived products to promote barrier integrity and reduce proinflammatory responses, followed by oral supplementation with a relatively simple and defined inoculum of microbial species to promote appropriate microbiome (re)development. Probiotics have gained enormous interest in recent years as a means to promote intestinal homeostasis; however, much more work is needed to fully elucidate their mechanism(s) of action. The observations reported in this study are important because they provide initial evidence for promotion of barrier function via probiotic-derived products. Understanding the mechanism(s) by which microbes and their products beneficially alter host physiology holds much promise for a broad range of conditions, not least as a precursor treatment for highly vulnerable populations such as premature neonates at high risk of necrotizing enterocoilitis.

Surface proteins of Bifidobacterium bifidum DNG6 growing in 2'-fucosyllactose alleviating lipopolysaccharide-induced intestinal barrier injury in vitro

Preparation and synbiotic interaction mechanism of microcapsules of Bifidobacterium animalis F1-7 and human milk oligosaccharides (HMO)

Protective effects of Bifidobacterium bifidum FL-228.1 on dextran sulfate sodium-induced intestinal damage in mice

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

2′-Fucosyllactose Ameliorates Inflammatory Bowel Disease by Modulating Gut Microbiota and Promoting MUC2 Expression

Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum

Bifidobacterium dentium N8 with potential probiotic characteristics prevents LPS-induced intestinal barrier injury by alleviating the inflammatory response and regulating the tight junction in Caco-2 cell monolayers

Bifidobacterium bifidum Ameliorates DSS-Induced Colitis in Mice by Regulating AHR/NRF2/NLRP3 Inflammasome Pathways through Indole-3-lactic Acid Production

Immunomodulatory effects of the Bifidobacterium longum BL-10 on lipopolysaccharide-induced intestinal mucosal immune injury

2'-Fucosyllactose Promotes Colonization of Akkermansia muciniphila and Prevents Colitis In Vitro and in Mice

Bifidobacterium breve Alleviates DSS-Induced Colitis in Mice by Maintaining the Mucosal and Epithelial Barriers and Modulating Gut Microbes

The Probiotic Strain Bifidobacterium animalis ssp. lactis HY8002 Potentially Improves the Mucosal Integrity of an Altered Intestinal Microbial Environment

Protective Effects of Bifidobacterium on Intestinal Barrier Function in LPS-Induced Enterocyte Barrier Injury of Caco-2 Monolayers and in a Rat NEC Model

Lactobacillus rhamnosus CY12 Enhances Intestinal Barrier Function by Regulating Tight Junction Protein Expression, Oxidative Stress, and Inflammation Response in Lipopolysaccharide-Induced Caco-2 Cells

Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner

2′FL and LNnT Exert Antipathogenic Effects against C. difficile ATCC 9689 In Vitro, Coinciding with Increased Levels of Bifidobacteriaceae and/or Secondary Bile Acids

Intestinal Mucosal Barrier Improvement with Prebiotics: Histological Evaluation of Longish Glucomannan Hydrolysates-Induced Innate T Lymphocyte Activities in Mice

Novel Gut Microbiota Patterns Involved in the Attenuation of Dextran Sodium Sulfate-Induced Mouse Colitis Mediated by Glycerol Monolaurate via Inducing Anti-inflammatory Responses

Alleviation Effects of Bifidobacterium animalis subsp. lactis XLTG11 on Dextran Sulfate Sodium-Induced Colitis in Mice

Promotion of Epithelial Barrier Integrity Via Probiotic-derived Products.

Sialyllactose Enhances the Short-Chain Fatty Acid Production and Barrier Function of Gut Epithelial Cells via Nonbifidogenic Modification of the Fecal Microbiome in Human Adults